Dimethylbenz(a)anthracene-induced mammary tumorigenesis in mice

Methods Cell Biol. 2021:163:21-44. doi: 10.1016/bs.mcb.2020.09.003. Epub 2020 Oct 16.

Abstract

Every year, over 2 million women are diagnosed with breast cancer. Although considerable progress was made within the last years in cancer prevention, diagnosis and treatment, breast cancer is still responsible for over 600,000 of deaths per year. Over the years, numerous mouse models have been developed to understand breast cancer etiology and progression. Among those, mammary carcinomas induced by carcinogen, such as 7,12-dimethylbenz[a]anthracene (DMBA), has been widely used. Generally, 30-70% of mice exposed to 4-6 weekly doses of 1mg of DMBA during the peripubertal period (4-10 weeks of age) will develop mammary tumors within 150-200 days after the first exposure, that sometime metastasize to the lungs. As a result, DMBA-induced tumorigenesis is thought to be an accurate and relevant model to study breast cancer as it closely mimics this multistep process. This chapter presents the typical protocol used in mice to induce mammary gland tumors using DMBA. The influence of the number of doses and the total burden of DMBA given, as well as of the age and strain of the mice on mammary gland incident and on tumor onset are discussed. The current knowledge regarding mechanisms involved in DMBA-induced tumorigenesis is also presented.

Keywords: Breast cancer; Dimethylbenz(a)anthracene; Mammary gland; Peripubertal; Protocol; Tumorigenesis.

MeSH terms

  • 9,10-Dimethyl-1,2-benzanthracene* / toxicity
  • Animals
  • Anthracenes
  • Carcinogenesis
  • Carcinogens / toxicity
  • Mammary Neoplasms, Experimental* / chemically induced
  • Mice

Substances

  • Anthracenes
  • Carcinogens
  • 9,10-Dimethyl-1,2-benzanthracene